FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953896279> ?p ?o ?g. }

• W2953896279 endingPage "541" @default.
• W2953896279 startingPage "531" @default.
• W2953896279 abstract "Hepatic encephalopathy (HE) is a complication of liver cirrhosis and can result in neuropsychological and neuromuscular dysfunctions in patients. Rifaximin, an antibiotic, has been reported to decrease the occurrence of overt HE and also improve cognitive function in studies from Europe and the United States of America. There is not enough evidence of the relationship between the long-term use of rifaximin and its clinical effects in the Japanese.To determine the clinical effects of long-term rifaximin therapy in decompensated liver cirrhosis patients, with overt HE or hyperammonemia.In this single-center retrospective observational cohort study, we reviewed the data of 38 patients who had taken rifaximin at the dose of 1200 mg/d for more than 24 wk. The primary outcome measured was the efficacy of long-term rifaximin use, and secondary outcome measured was the safety of its long-term use as determined by its influence on portosystemic shunts as well as Escherichia coli-related infections. Moreover, we compared the prognosis between the rifaximin group and control cases, matched for hepatic elasticity assessed by magnetic resonance ela-stography, age, and Child-Pugh classification.Of the 38 patients included in the study, 12 (31.6%) had overt HE, 27 (71.1%) had complications of esophageal varices, and 9 (23.7%) had hepatocellular carcinoma (HCC). The control group was matched for age, Child-Pugh classification, liver stiffness, and presence of HCC. The median of serum ammonia level before treatment was 104 μg/dL (59-297), and 2 wk after treatment, it significantly decreased to 85 μg/dL (34-153) (P = 0.002). A significantly low value of 80.5 μg/dL (44-150) was maintained 24 wk after treatment. The long-term use of rifaximin did not cause a decline in liver function. Diarrhea occurred in 2 patients, who improved with the administration of probiotics, and there were no cases of aborted rifaximin therapy owing to adverse events. In patients with Child C, the survival was short, but there was no significant difference compared with that of the control group.Rifaximin therapy improves overt HE. The long-term use of rifaximin in the Japanese is effective and safe." @default.
• W2953896279 created "2019-07-12" @default.
• W2953896279 creator A5003323860 @default.
• W2953896279 creator A5031464686 @default.
• W2953896279 creator A5071497400 @default.
• W2953896279 creator A5076340516 @default.
• W2953896279 creator A5081789703 @default.
• W2953896279 creator A5086576782 @default.
• W2953896279 creator A5086836298 @default.
• W2953896279 creator A5091293654 @default.
• W2953896279 date "2019-06-27" @default.
• W2953896279 modified "2023-09-25" @default.
• W2953896279 title "Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese" @default.
• W2953896279 cites W1973051170 @default.
• W2953896279 cites W1982702940 @default.
• W2953896279 cites W2002870137 @default.
• W2953896279 cites W2003796334 @default.
• W2953896279 cites W2013949328 @default.
• W2953896279 cites W2025612159 @default.
• W2953896279 cites W2025707289 @default.
• W2953896279 cites W2026317976 @default.
• W2953896279 cites W2057169806 @default.
• W2953896279 cites W2081927032 @default.
• W2953896279 cites W2083585063 @default.
• W2953896279 cites W2091958019 @default.
• W2953896279 cites W2099360240 @default.
• W2953896279 cites W2103280958 @default.
• W2953896279 cites W2105932465 @default.
• W2953896279 cites W2116332678 @default.
• W2953896279 cites W2117827638 @default.
• W2953896279 cites W2170325206 @default.
• W2953896279 cites W2741614590 @default.
• W2953896279 cites W2764317885 @default.
• W2953896279 cites W2774313276 @default.
• W2953896279 cites W2784907329 @default.
• W2953896279 cites W2805536661 @default.
• W2953896279 cites W2941252878 @default.
• W2953896279 doi "https://doi.org/10.4254/wjh.v11.i6.531" @default.
• W2953896279 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6603506" @default.
• W2953896279 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31293721" @default.
• W2953896279 hasPublicationYear "2019" @default.
• W2953896279 type Work @default.
• W2953896279 sameAs 2953896279 @default.
• W2953896279 citedByCount "12" @default.
• W2953896279 countsByYear W29538962792020 @default.
• W2953896279 countsByYear W29538962792021 @default.
• W2953896279 countsByYear W29538962792022 @default.
• W2953896279 countsByYear W29538962792023 @default.
• W2953896279 crossrefType "journal-article" @default.
• W2953896279 hasAuthorship W2953896279A5003323860 @default.
• W2953896279 hasAuthorship W2953896279A5031464686 @default.
• W2953896279 hasAuthorship W2953896279A5071497400 @default.
• W2953896279 hasAuthorship W2953896279A5076340516 @default.
• W2953896279 hasAuthorship W2953896279A5081789703 @default.
• W2953896279 hasAuthorship W2953896279A5086576782 @default.
• W2953896279 hasAuthorship W2953896279A5086836298 @default.
• W2953896279 hasAuthorship W2953896279A5091293654 @default.
• W2953896279 hasBestOaLocation W29538962791 @default.
• W2953896279 hasConcept C126322002 @default.
• W2953896279 hasConcept C167135981 @default.
• W2953896279 hasConcept C2777214474 @default.
• W2953896279 hasConcept C2777595160 @default.
• W2953896279 hasConcept C2778019345 @default.
• W2953896279 hasConcept C2778808290 @default.
• W2953896279 hasConcept C2778889925 @default.
• W2953896279 hasConcept C2780325230 @default.
• W2953896279 hasConcept C2780496750 @default.
• W2953896279 hasConcept C2781099255 @default.
• W2953896279 hasConcept C501593827 @default.
• W2953896279 hasConcept C71924100 @default.
• W2953896279 hasConcept C86803240 @default.
• W2953896279 hasConcept C89423630 @default.
• W2953896279 hasConcept C90924648 @default.
• W2953896279 hasConceptScore W2953896279C126322002 @default.
• W2953896279 hasConceptScore W2953896279C167135981 @default.
• W2953896279 hasConceptScore W2953896279C2777214474 @default.
• W2953896279 hasConceptScore W2953896279C2777595160 @default.
• W2953896279 hasConceptScore W2953896279C2778019345 @default.
• W2953896279 hasConceptScore W2953896279C2778808290 @default.
• W2953896279 hasConceptScore W2953896279C2778889925 @default.
• W2953896279 hasConceptScore W2953896279C2780325230 @default.
• W2953896279 hasConceptScore W2953896279C2780496750 @default.
• W2953896279 hasConceptScore W2953896279C2781099255 @default.
• W2953896279 hasConceptScore W2953896279C501593827 @default.
• W2953896279 hasConceptScore W2953896279C71924100 @default.
• W2953896279 hasConceptScore W2953896279C86803240 @default.
• W2953896279 hasConceptScore W2953896279C89423630 @default.
• W2953896279 hasConceptScore W2953896279C90924648 @default.
• W2953896279 hasIssue "6" @default.
• W2953896279 hasLocation W29538962791 @default.
• W2953896279 hasLocation W29538962792 @default.
• W2953896279 hasLocation W29538962793 @default.
• W2953896279 hasLocation W29538962794 @default.
• W2953896279 hasOpenAccess W2953896279 @default.
• W2953896279 hasPrimaryLocation W29538962791 @default.
• W2953896279 hasRelatedWork W2019735654 @default.
• W2953896279 hasRelatedWork W2037872940 @default.
• W2953896279 hasRelatedWork W2102592290 @default.

• next